PDF(Pubmed)
Abstract：
The immunotherapy for gastrointestinal tumors, as a significant research direction in the field of oncology treatment in recent years, has garnered extensive attention due to its potential therapeutic efficacy and promising clinical application prospects. Recent advances in immunotherapy notwithstanding, challenges persist, such as side effects, the complexity of the tumor immune microenvironment, variable patient responses, and drug resistance. Consequently, there is a pressing need to explore novel adjunctive therapeutic modalities. β-glucan, an immunomodulatory agent, has exhibited promising anti-tumor efficacy in preclinical studies involving colorectal cancer, pancreatic cancer, and gastric cancer, while also mitigating the adverse reactions associated with chemotherapy and enhancing patients\' quality of life. However, further clinical and fundamental research is warranted to comprehensively evaluate its therapeutic potential and underlying biological mechanisms. In the future, β-glucan holds promise as an adjunctive treatment for gastrointestinal tumors, potentially bringing significant benefits to patients.
摘要：
胃肠道肿瘤的免疫治疗，作为近年来肿瘤治疗领域的重要研究方向,由于其潜在的治疗效果和有希望的临床应用前景,受到了广泛的关注。尽管免疫治疗的最新进展，挑战依然存在,如副作用，肿瘤免疫微环境的复杂性，可变的患者反应，和抗药性。因此,迫切需要探索新的辅助治疗方式。β-葡聚糖,一种免疫调节剂，在涉及结直肠癌的临床前研究中表现出了有希望的抗肿瘤功效，胰腺癌,和胃癌，同时减轻与化疗相关的不良反应，提高患者的生活质量。然而,需要进一步的临床和基础研究来全面评估其治疗潜力和潜在的生物学机制.在未来,β-葡聚糖有望作为胃肠道肿瘤的辅助治疗，可能给患者带来显著的好处。
